Larotin, Fe S.

HRN: 22-25-85  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/29/2022
CEFTRIAXONE 1G (VIAL)
11/29/2022
12/05/2022
IV
2g
Q24
Bleeding And Infected & Breast Mass
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: